Comparison of Paclitaxel-Eluting Coroflex Please Stent Versus Paclitaxel-Eluting Stent

Exclusion Criteria

• •The patient has a known hypersensitivity or contraindication to any of the following medications:
• •* Heparin
• •* Aspirin
• •* Both Clopidogrel and TIclopidine
• •* Sirolimus, paclitaxel
• •* Stainless steel and/or
• •* Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled)
• •Systemic (intravenous) Sirolimus or paclitaxel use within 12 months
• •Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
• •History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions
• •Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months
• •Current known current platelet count \<100,000 cells/mm3 or Hgb \<10 g/dL
• •An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 12 months post enrollment
• •Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
• •Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
• •Patients with EF\<25%
• •Cardiogenic shock at entry
• •Acute MI patients within symptom onset \< 12 hours needing primary angioplasty
• •Creatinine level \> 3.0mg/dL or dependence on dialysis
• •Patients with left main stem stenosis (\>50% by visual estimate)